Vergrote kans op overlijden van ernstig zieke patiënten na behandeling met humaan albumine?

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 33, 1998, Pages 1855-1858

  Offkinga, M ^a   Gfmke En, R J B J ^a   Henny, C P ^a  

^a Acüdemisch Mcdisch Centrum

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; PLASMA PROTEIN; PLASMA SUBSTITUTE; SERUM ALBUMIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRITICAL ILLNESS; DRUG EFFECT; FEMALE; HUMAN; MALE; MORTALITY; OSMOLARITY; PLASMA VOLUME; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SHOCK; STANDARD; SURVIVAL RATE;

ALBUMINS; BLOOD PROTEINS; CRITICAL ILLNESS; FEMALE; GUIDELINES; HUMANS; MALE; OSMOLAR CONCENTRATION; PLASMA SUBSTITUTES; PLASMA VOLUME; RANDOMIZED CONTROLLED TRIALS; SERUM ALBUMIN; SHOCK; SURVIVAL RATE;

EID: 0032528662     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. McCluskcy A, Thomas AN, Bewies BJ, Kishen R. The prognostic value of serial measurements of serum albumin concentration in patients admitted to an intensive care unit. Anaesthesia 1996:51: 724-7.
2. The Albumin Reviewers. Human albumin administration in critically ill patients. The Cochrane Library 1998. issue 3. Oxford: Update Software. 1498.
3. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998:317:235-40.
4. Oxman AD. Cook DL. Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. JAMA 1994:272:1367-71.
5. Sackett DL, Richardson WS. Rosenberg W, Haynes RB. Evidencebased medicine: how to practice and teach EBM. Edinburgh: Churchill Livingstone. 1996:91-9.
6. Offringa M. Excess mortality after human albumin administration in critically ill patients. BMJ 1998:317:223-4.
7. Moss GS. Das Gupta TK, Brinkman R, Schgal L. Newsom B. Changes in lung ultrastructure following heterologous and homologous serum albumin infusion in the treatment of hemorrhagic shock. Ann Surg 1979:189:236-42.
8. Johnson SD. Lucas CE, Gerrick SJ, Ledgerwood AM. Higgins RF. Altered coagulation after albumin supplements for treatment of oligemic shock. Arch Surg 1979:114:379-83.
9. Moon MR. Lucas CE. Ledgerwood AM, Kosinski JP. Free water clearance after supplemental albumin resuscitation for shock. Circ Shock 1989:28:1-8.
10. Köhler W. Dodelijk redmiddcl. NRC Handelsblad 25 juli 1998.
11. Sirchia G. Giovanetti AM, McCelland DBL. Fracchia GN. editors. Safe and good use of blood in surgery (SANGUIS). Use of blood products and artificial colloids in 43 European hospitals. Brüssel: The European Commission. 1994:19-29.
12. Boldt J. Muller M. Mentges D. Papsdorf M, Hempelmann G. Volume therapy in the critically ill: is there a difference? Intensive Care Mcd 1998:24:28-36.
13. Falk JL. Rackow EC. Astix ME, Weil MH. Effects of hetastarch and albumin on coagulation in patients with septic shoek. J Clin Pharmacol 1988:28:412-5.
14. Jonge E de. Levi M, Berends F, Ende AE van der. Cate JW ten. Stoutenbeek CP. Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost 1998:79:286-90.
15. Smorenburg CH. Wee PM ter, Gans ROB. Klinische toepassmg van albumine: indicalies nader bckekcn. Ned Tijdschr Geneeskd 1997:141:719-23.
16. Kaag MM, Zoetmulder FAN. Klinische toepassing van albumine: indicaties nader bekeken [ingezonden]. Ned Tijdschr Geneeskd 1997:141:1308-9.